ArticleJournal of inflammation research2026
R788 is Associated with Neuroprotective Effects in Experimental Ischemic Stroke Models via Modulation of the STAT1/Nrf2/GPX4 Axis.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Thymosin β4 Mitigates Acute Cerebral Infarction Via Inhibition of the TLR4/NF-κB Pathway and Suppression of Neuronal Pyroptosis.Applied biochemistry and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ischemic stroke, the most prevalent form of cerebrovascular disease, stands as a leading global cause of both disability and mortality. Oxidative stress damage is a critical pathological mechanism in stroke, and regulated cell death may be an effective therapeutic target for treating ischemic stroke. This work provides the first evidence that R788, a small-molecule inhibitor of spleen tyrosine kinase, exerts therapeutic efficacy in ischemic stroke, thereby unveiling a novel mechanistic basis and potential strategy for intervention. Methods: The antioxidant defense and anti-apoptotic effects of R788 were assessed in a middle cerebral artery occlusion (MCAO) animal model and an H Results: The results showed that both in the animal and cell models, the R788-treated group had an increased number of surviving SH-SY5Y cells compared to the control group. Additionally, the R788 group showed the inhibition of p-STAT1 and suppressed ferroptosis. We confirmed that R788 treatment alleviated oxidative stress damage by inhibiting ferroptosis-related pathways, thereby promoting cell survival. In summary, R788 demonstrated neuroprotective effects against ischemia-induced neural injury in both in vivo and in vitro models. Conclusion: Our workss suggest that R788 alleviate localized ischemic injury and oxidative stress damage by regulating STAT1/Nrf2/GPX4 pathways. These findings indicate that R788 shows potential for the treatment of IS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.